Improving treatment for chronic myeloid leukemia with targeted therapies
Official title: Understanding critical transitions in chronic myeloid leukemia to improve tyrosine kinase inhibitor therapy
Funded at University of California-Irvine · NIH-11016818 · Data updated 2026-11-12
This study is looking for ways to help people with chronic myeloid leukemia (CML) respond better to their main treatment, tyrosine kinase inhibitors (TKIs), especially during the first year after they are diagnosed, so that more patients can achieve a lasting remission and possibly a cure.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California-Irvine NIH-funded |
| Lab location | 1 site (Irvine, United States) |
| Project start | April 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $505,549 |
| NIH project number | 1P01CA288662-01A1 |
| Project ID | NIH-11016818 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with chronic myeloid leukemia who are starting treatment with tyrosine kinase inhibitors.
✕Less likely to help
Patients with chronic myeloid leukemia who are not eligible for tyrosine kinase inhibitor therapy or those with advanced stages of the disease may not benefit from this research.
What this research studies
This research focuses on chronic myeloid leukemia (CML), a type of blood cancer that affects around 5,000 Americans each year. It aims to enhance the effectiveness of tyrosine kinase inhibitors (TKIs), which are the primary treatment for CML, by identifying strategies to improve patient responses during the critical first year after diagnosis. The study will explore the mechanisms behind resistance to TKIs and seek to find ways to help more patients achieve treatment-free remission, potentially leading to a cure. Patients may be involved in understanding their responses to therapy and the factors influencing their treatment outcomes.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for CML, enhancing patient outcomes and potentially allowing some patients to stop therapy without relapse.
How similar studies have gone: Previous research has shown promising results in improving treatment outcomes for CML using similar approaches, indicating a potential for significant advancements in this area.
Where this research is happening
-
University of California-Irvine
Irvine, United States Active
Researchers
- Principal investigator: Van Etten, Richard a. — University of California-Irvine
- Study coordinator: Van Etten, Richard a.
Related research
Other NIH-funded projects on the same topics.
-
Chronic myeloid leukemia: how T cells and leukemia stem cells interact during treatment
This NIH grant explores how immune cells and stubborn leukemia stem cells interact during therapy to better predict if patients can stay off treatment.
-
Targeting DYRK2 to kill leukemia stem cells in CML
Aims to find ways to remove leukemia stem cells in chronic myeloid leukemia by boosting a protein (DYRK2) that can halt their growth.
-
Why chronic myeloid leukemia sometimes resists treatment and how to improve TKI care
This project looks at why some people with chronic myeloid leukemia respond differently to tyrosine kinase inhibitor drugs and aims to help more patients get deeper, longer-lasting remissions.
-
Targeting a specific protein to eliminate leukemia stem cells in chronic myeloid leukemia.
This study is looking at a new way to help people with chronic myeloid leukemia (CML) by focusing on a protein called DYRK2, which could help make leukemia stem cells less likely to survive, so patients might be able to stop their current treatments without their cancer coming back.
-
Understanding how some patients with chronic myeloid leukemia can remain healthy without treatment
This study is looking into why some people with chronic myeloid leukemia can stay healthy without taking their medication, using mice to find out what helps them maintain remission, which could lead to better ways to manage the condition and lessen the need for long-term treatment.
-
Targeting a specific protein to treat chronic myeloid leukemia
This study is testing a new small protein that could help stop a key protein linked to chronic myeloid leukemia from working against you, and if it works, it might offer a fresh treatment option for patients like you.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.